SS-31 attenuates TNF-α induced cytokine release from C2C12 myotubes

Redox Biology

Volumn 6, Issue , 2015, Pages 253-259

  Lightfoot, Adam P ^a   Sakellariou, Giorgos K ^a   Nye, Gareth A ^a   McArdle, Francis ^a   Jackson, Malcolm J ^a   Griffiths, Richard D ^a   McArdle, Anne ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

C2C12; Myokine; Skeletal muscle; Superoxide; TNF

Indexed keywords

BREFELDIN A; CXCL1 CHEMOKINE; CYTOKINE; ELAMIPRETIDE; I KAPPA B KINASE ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; MYOKINE; RANTES; REACTIVE OXYGEN METABOLITE; SALICYLATE SODIUM; SUPEROXIDE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ARGINYL-2,'6'-DIMETHYLTYROSYL-LYSYL-PHENYLALANINAMIDE; CCL2 PROTEIN, MOUSE; CCL5 PROTEIN, MOUSE; CXCL1 PROTEIN, MOUSE; INTERLEUKIN-6, MOUSE; OLIGOPEPTIDE; SCAVENGER; TUMOR NECROSIS FACTOR;

ARTICLE; CCL2 GENE; CCL5 GENE; CELL VIABILITY; CONTROLLED STUDY; CXCL1 GENE; CYTOKINE PRODUCTION; CYTOKINE RELEASE; GENE EXPRESSION; GOLGI COMPLEX; MITOCHONDRION; MYOTUBE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN LOCALIZATION; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL LINE; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MOUSE; SIGNAL TRANSDUCTION; SKELETAL MUSCLE CELL;

ANIMALS; BREFELDIN A; CELL LINE; CHEMOKINE CCL2; CHEMOKINE CCL5; CHEMOKINE CXCL1; FREE RADICAL SCAVENGERS; GENE EXPRESSION REGULATION; GOLGI APPARATUS; INTERLEUKIN-6; MICE; MITOCHONDRIA; MUSCLE FIBERS, SKELETAL; NF-KAPPA B; OLIGOPEPTIDES; SIGNAL TRANSDUCTION; SUPEROXIDES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84940021145     PISSN: 22132317     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.redox.2015.08.007     Document Type: Article

References (50)

1. Bhatnagar S., Panguluri S.K., Gupta S.K., Dahiya S., Lundy R.F., Kumar A. Tumor necrosis factor-alpha regulates distinct molecular pathways and gene networks in cultured skeletal muscle cells. PLoS One 2010, 5(10):e13262.
2. Henningsen J., Rigbolt K.T., Blagoev B., Pedersen B.K., Kratchmarova I. Dynamics of the skeletal muscle secretome during myoblast differentiation. Mol. Cell. Proteomics 2010, 9(11):2482-2496.
3. Yoon J.H., Song P., Jang J.H., Kim D.K., Choi S., Kim J., et al. Proteomic analysis of tumor necrosis factor-alpha (TNF-alpha)-induced L6 myotube secretome reveals novel TNF-alpha-dependent myokines in diabetic skeletal muscle. J. Proteome Res. 2011, 10(12):5315-5325.
4. Pedersen B.K., Febbraio M.A. Muscle as an endocrine organ: focus on muscle-derived interleukin-6. Physiol. Rev. 2008, 88(4):1379-1406.
5. Lacy P., Stow J.L. Cytokine release from innate immune cells: association with diverse membrane trafficking pathways. Blood 2011, 118(1):9-18.
6. Nielsen S., Pedersen B.K. Skeletal muscle as an immunogenic organ. Curr. Opin. Pharmacol. 2008, 8(3):346-351.
7. Pedersen B.K. Muscular interleukin-6 and its role as an energy sensor. Med. Sci. Sports Exerc. 2012, 44(3):392-396.
8. Griffiths R.D., McArdle A. Keeping up the defenses. Nutrition 2004, 20(6):587-589.
9. Lang C.H., Frost R.A., Vary T.C. Regulation of muscle protein synthesis during sepsis and inflammation. Am. J. Physiol. Endocrinol. Metab. 2007, 293(2):E453-E459.
10. Reid M.B., Moylan J.S. Beyond atrophy: redox mechanisms of muscle dysfunction in chronic inflammatory disease. J. Physiol. 2011, 589(Pt 9):2171-2179.
11. Tang K., Wagner P.D., Breen E.C. TNF-alpha-mediated reduction in PGC-1alpha may impair skeletal muscle function after cigarette smoke exposure. J. Cell. Physiol. 2010, 222(2):320-327.
12. Roubenoff R. Catabolism of aging: is it an inflammatory process?. Curr. Opin. Clin. Nutr. Metab. Care 2003, 6(3):295-299.
13. Li Y.P., Chen Y., John J., Moylan J., Jin B., Mann D.L., et al. TNF-alpha acts via p38 MAPK to stimulate expression of the ubiquitin ligase atrogin1/MAFbx in skeletal muscle. FASEB J. 2005, 19(3):362-370.
14. McNicol F.J., Hoyland J.A., Cooper R.G., Carlson G.L. Skeletal muscle contractile properties and proinflammatory cytokine gene expression in human endotoxaemia. Br. J. Surg. 2010, 97(3):434-442.
15. Jackman R.W., Kandarian S.C. The molecular basis of skeletal muscle atrophy. Am. J. Physiol. Cell Physiol. 2004, 287(4):C834-C843.
16. Ladner K.J., Caligiuri M.A., Guttridge D.C. Tumor necrosis factor-regulated biphasic activation of NF-kappa B is required for cytokine-induced loss of skeletal muscle gene products. J. Biol. Chem. 2003, 278(4):2294-2303.
17. Cai D., Frantz J.D., Tawa N.E., Melendez P.A., Oh B.C., Lidov H.G., et al. IKKbeta/NF-kappaB activation causes severe muscle wasting in mice. Cell 2004, 119(2):285-298.
18. Guttridge D.C., Mayo M.W., Madrid L.V., Wang C.Y., Baldwin A.S. NF-kappaB-induced loss of MyoD messenger RNA: possible role in muscle decay and cachexia. Science 2000, 289(5488):2363-2366.
19. Yamaki T., Wu C.L., Gustin M., Lim J., Jackman R.W., Kandarian S.C. Rel A/p65 is required for cytokine-induced myotube atrophy. Am. J. Physiol. Cell Physiol. 2012, 303(2):C135-C142.
20. Li Y.P., Reid M.B. NF-kappaB mediates the protein loss induced by TNF-alpha in differentiated skeletal muscle myotubes. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2000, 279(4):R1165-R1170.
21. Li Y.P., Schwartz R.J., Waddell I.D., Holloway B.R., Reid M.B. Skeletal muscle myocytes undergo protein loss and reactive oxygen-mediated NF-kappaB activation in response to tumor necrosis factor alpha. FASEB J. 1998, 12(10):871-880.
22. Goossens V., Grooten J., De Vos K., Fiers W. Direct evidence for tumor necrosis factor-induced mitochondrial reactive oxygen intermediates and their involvement in cytotoxicity. Proc. Natl. Acad. Sci. USA 1995, 92(18):8115-8119.
23. Lacerda L., Smith R.M., Opie L., Lecour S. TNFalpha-induced cytoprotection requires the production of free radicals within mitochondria in C2C12 myotubes. Life Sci. 2006, 79(23):2194-2201.
24. Scheele C., Nielsen S., Pedersen B.K. ROS and myokines promote muscle adaptation to exercise. Trends Endocrinol. Metab. 2009, 20(3):95-99.
25. Kosmidou I., Vassilakopoulos T., Xagorari A., Zakynthinos S., Papapetropoulos A., Roussos C. Production of interleukin-6 by skeletal myotubes: role of reactive oxygen species. Am. J. Respir. Cell Mol. Biol. 2002, 26(5):587-593.
26. Hardin B.J., Campbell K.S., Smith J.D., Arbogast S., Smith J., Moylan J.S., et al. TNF-alpha acts via TNFR1 and muscle-derived oxidants to depress myofibrillar force in murine skeletal muscle. J. Appl. Physiol. 2008, 104(3):694-699.
27. Yaffe D., Saxel O. Serial passaging and differentiation of myogenic cells isolated from dystrophic mouse muscle. Nature 1977, 270(5639):725-727.
28. Maglara A.A., Vasilaki A., Jackson M.J., McArdle A. Damage to developing mouse skeletal muscle myotubes in culture: protective effect of heat shock proteins. J. Physiol. (Lond.) 2003, 548(Pt 3):837-846.
29. Sakellariou G.K., Vasilaki A., Palomero J., Kayani A., Zibrik L., McArdle A., et al. Studies of mitochondrial and nonmitochondrial sources implicate nicotinamide adenine dinucleotide phosphate oxidase(s) in the increased skeletal muscle superoxide generation that occurs during contractile activity. Antioxid. Redox Signal. 2013, 18(6):603-621.
30. Robinson K.M., Janes M.S., Pehar M., Monette J.S., Ross M.F., Hagen T.M., et al. Selective fluorescent imaging of superoxide in vivo using ethidium-based probes. Proc. Natl. Acad. Sci. USA 2006, 103(41):15038-15043.
31. Chomczynski P., Sacchi N. The single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction: twenty-something years on. Nat. Protoc. 2006, 1(2):581-585.
32. McArdle A., Pattwell D., Vasilaki A., Griffiths R.D., Jackson M.J. Contractile activity-induced oxidative stress: cellular origin and adaptive responses. Am. J. Physiol. Cell Physiol. 2001, 280(3):C621-C627.
33. Bostrom P., Wu J., Jedrychowski M.P., Korde A., Ye L., Lo J.C., et al. A PGC1-alpha-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature 2012, 481(7382):463-468.
34. De Rossi M., Bernasconi P., Baggi F., de Waal Malefyt R., Mantegazza R. Cytokines and chemokines are both expressed by human myoblasts: possible relevance for the immune pathogenesis of muscle inflammation. Int. Immunol. 2000, 12(9):1329-1335.
35. Starkie R., Ostrowski S.R., Jauffred S., Febbraio M., Pedersen B.K. Exercise and IL-6 infusion inhibit endotoxin-induced TNF-alpha production in humans. FASEB J. 2003, 17(8):884-886.
36. Haddad F., Zaldivar F., Cooper D., Adams G. IL-6-induced skeletal muscle atrophy. J. Appl. Physiol. (Bethesda, Md: 1985) 2005, 98(3):911-917.
37. Riedemann N., Neff T., Guo R.-F., Bernacki K., Laudes I., Sarma J., et al. Protective effects of IL-6 blockade in sepsis are linked to reduced C5a receptor expression. J. Immunol. (Baltimore, Md: 1950) 2003, 170:503-507.
38. Henningsen J., Pedersen B., Kratchmarova I. Quantitative analysis of the secretion of the MCP family of chemokines by muscle cells. Mol. BioSyst. 2011, 7(2):311-321.
39. Civatte M., Bartoli C., Schleinitz N., Chetaille B., Pellissier J., Figarella-Branger D. Expression of the beta chemokines CCL3, CCL4, CCL5 and their receptors in idiopathic inflammatory myopathies. Neuropathol. Appl. Neurobiol. 2005, 31(1):70-79.
40. Demoule A., Divangahi M., Danialou G., Gvozdic D., Larkin G., Bao W., et al. Expression and regulation of CC class chemokines in the dystrophic (mdx) diaphragm. Am. J. Respir. Cell Mol. Biol. 2005, 33(2):178-185.
41. Beyer I., Njemini R., Bautmans I., Demanet C., Bergmann P., Mets T. Inflammation-related muscle weakness and fatigue in geriatric patients. Exp. Gerontol. 2012, 47(1):52-59.
42. Shireman P., Contreras-Shannon V., Ochoa O., Karia B., Michalek J., McManus L. MCP-1 deficiency causes altered inflammation with impaired skeletal muscle regeneration. J. Leukoc. Biol. 2007, 81(3):775-785.
43. Kohno S., Ueji T., Abe T., Nakao R., Hirasaka K., Oarada M., et al. Rantes secreted from macrophages disturbs skeletal muscle regeneration after cardiotoxin injection in Cbl-b-deficient mice. Muscle Nerve 2011, 43(2):223-229.
44. Pedersen L., Olsen C.H., Pedersen B.K., Hojman P. Muscle-derived expression of the chemokine CXCL1 attenuates diet-induced obesity and improves fatty acid oxidation in the muscle. Am. J. Physiol. Endocrinol. Metab. 2012, 302(7):E831-E840.
45. Peterson J., Feeback K., Baas J., Pizza F. Tumor necrosis factor-alpha promotes the accumulation of neutrophils and macrophages in skeletal muscle. J. Appl.Physiol. (Bethesda, Md: 1985) 2006, 101(5):1394-1399.
46. Li Y.P., Atkins C.M., Sweatt J.D., Reid M.B. Mitochondria mediate tumor necrosis factor-alpha/NF-kappaB signaling in skeletal muscle myotubes. Antioxid. Redox Signal. 1999, 1(1):97-104.
47. Hayden M.S., Ghosh S. NF-kappaB in immunobiology. Cell Res. 2011, 21(2):223-244.
48. Dai D.F., Chen T., Szeto H., Nieves-Cintron M., Kutyavin V., Santana L.F., et al. Mitochondrial targeted antioxidant peptide ameliorates hypertensive cardiomyopathy. J. Am. Coll. Cardiol. 2011, 58(1):73-82.
49. Maack C., Bohm M. Targeting mitochondrial oxidative stress in heart failure. J. Am. Coll. Cardiol. 2011, 58(1):83-86.
50. Szeto H.H. First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics. Br. J. Pharmacol. 2014, 171(8):2029-2050.